---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011642"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2023-04-10T23:59:59+00:00"
generated_at: "2026-06-17T04:02:58.818918+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma completes $4M private placement of common stock at $1.97/share

## Summary
- Sold 2,030,458 shares at $1.97 each for total proceeds of $4.0 million.
- Investors: director/co-founder Phillip Frost and Fred Hassan (Caret Group, Warburg Pincus), each investing $2.0 million.
- Net proceeds to advance preclinical/clinical antiviral programs and for working capital.
- Company preparing for Phase 2a influenza A study (CC-42344) and first-in-human COVID-19 trial (CDI-988) in 2023.

## SEC filing metadata
- accession: 0001493152-23-011642
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2023-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/0001493152-23-011642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011642
- JSON: https://secwatch.observer/filing/0001493152-23-011642.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011642.txt

## Key facts
- Material Agreements
  Cocrystal Pharma, Inc. entered into Securities Purchase Agreement with Fred Hassan and Frost Gamma Investments Trust valued at $4,000,000 (effective 2023-04-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Fred Hassan and Frost Gamma Investments Trust
  - Value: $4,000,000
  - Effective: 2023-04-04
  source text: On April 4, 2023, Cocrystal Pharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with two accredited investors (the “Purchasers”) whereby the Purchasers agreed to purchase a total of 2,030,458 shares of common stock at a price of $1.97 per share for a total purchase price of $4,000,000 in two equal $2,000,000 investments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1412486/000149315223011642/0001493152-23-011642-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.